Case Study

Treatment-Resistant Depression Study 

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

CNS

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

CNS

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

CNS

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

CNS

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

CNS

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

CNS

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).
Case Study

Treatment-Resistant Depression Study 

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

CNS

Challenge

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality.

Solution

  • Protocol was purposely designed to reduce patient burden: Site visits were significantly reduced.
  • Combination of ePRO and eClinRO offered a more complete picture of QoL impact.
  • Safety tracking was meticulous: If a participant indicated suicidal ideations, an immediate alert was sent to the site team.
  • Site teams across Australia and New Zealand were trained extensively on the ObvioHealth platform, and ongoing communications with our study team ensured they were effectively supported.

ObvioHealth delivered the evidence needed to submit a bid for approval to Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).